Tysabri IV (Northern Ireland)
Tysabri IV (Northern Ireland) Uses, Dosage, Side Effects, Food Interaction and all others data.
Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Tysabri IV (Northern Ireland) contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Tysabri IV (Northern Ireland) was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006.
In multiple sclerosis, lesions are believed to occur when activated inflammatory cells, including T-lymphocytes, cross the blood-brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells, and their counter-receptors present on endothelial cells of the vessel wall. The clinical effect of natalizumab in multiple sclerosis may be a secondary result of its blockade of the molecular interaction of a 4b 1-integrin expressed by inflammatory cells with VCAM-1 on vascular endothelial cells, and with CS-1 and/or osteopontin expressed by parenchymal cells in the brain. α4-integrin is required for white blood cells to move into organs, therefore, natalizumab prevents these immune cells from crossing blood vessel walls to reach affected organs thereby decreasing inflamation.
| Trade Name | Tysabri IV (Northern Ireland) |
| Availability | Prescription only |
| Generic | Natalizumab |
| Natalizumab Other Names | Anti-alpha4 integrin, Anti-VLA4, Natalizumab |
| Related Drugs | Tysabri, Entyvio, Humira, Gilenya, Vumerity, budesonide, azathioprine, Remicade, Copaxone, Tecfidera |
| Type | |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | Biogen Idec Ltd |
| Available Country | United Kingdom |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Tysabri IV (Northern Ireland) is a monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis.
For treatment of multiple sclerosis.
Tysabri IV (Northern Ireland) is also used to associated treatment for these conditions: Relapsing Remitting Multiple Sclerosis (RRMS)
How Tysabri IV (Northern Ireland) works
Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s).
Food Interaction
No interactions found.Tysabri IV (Northern Ireland) Drug Interaction
Major: interferon beta-1a, dimethyl fumarateUnknown: 5-hydroxytryptophan, aspirin, charcoal, amphetamine / dextroamphetamine, fluticasone / salmeterol, diphenhydramine / ibuprofen, naproxen, diphenhydramine / naproxen, fexofenadine, acetaminophen, celecoxib, gabapentin, omega-3 polyunsaturated fatty acids, acetaminophen, vitamin a topical, methylphenidate, cholecalciferol, lisdexamfetamine
Tysabri IV (Northern Ireland) Disease Interaction
Major: infections, PMLModerate: liver dysfunction, meningitis
Volume of Distribution
- 5.7 ± 1.9 L [Multiple Sclerosis (MS) Patients]
- 5.2 ± 2.8 L [Crohn's Disease (CD) Patients]
Half Life
11 ± 4 days
Clearance
- 16 +/- 5 mL/hour [patients with MS who did not have PML receiving the repeat IV administration of a 300 mg dose]
- 22 +/- 22 mL/hour [Patients with Crohn's Disease receiving the repeat IV administration of a 300 mg dose]
Innovators Monograph
You find simplified version here Tysabri IV (Northern Ireland)
